Can gabapentin cause hair loss? This is a question raised by many patients prescribed this widely used anticonvulsant and analgesic in the UK. Gabapentin (brand name Neurontin) is commonly prescribed for epilepsy and peripheral neuropathic pain, and whilst it has a well-characterised side effect profile, alopecia is not listed as a recognised adverse reaction in its MHRA-approved Summary of Product Characteristics. However, patient-reported experiences and the complexity of attributing hair loss to any single cause mean this concern deserves careful, evidence-based consideration. This article explores what the clinical evidence shows, what else may be responsible, and when to seek medical advice.

Is Hair Loss a Recognised Side Effect of Gabapentin?

Alopecia is not listed as a common or recognised side effect in gabapentin's MHRA-approved SmPC; the most frequently reported adverse effects are dizziness, somnolence, peripheral oedema, and ataxia.

Experiencing these side effects? Our pharmacists can help you navigate them →

Gabapentin (UK brand name Neurontin) is an anticonvulsant and analgesic medicine widely prescribed in the UK for epilepsy and peripheral neuropathic pain. It is also used off-label for other conditions, including restless legs syndrome, although this is not a licensed indication in the UK. Gabapentin works by binding to voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and thereby dampening abnormal nerve signalling.

Hair loss — medically termed alopecia — is not listed as a common side effect of gabapentin in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), which is the authoritative UK source for licensed indications and adverse reaction frequencies. The most frequently reported side effects of gabapentin include dizziness, somnolence, peripheral oedema, and ataxia. Alopecia does not appear as a common or well-recognised adverse reaction in the UK SmPC.

However, the absence of a side effect from official labelling does not mean it cannot occur. Rare or idiosyncratic reactions are sometimes reported by patients and healthcare professionals outside of clinical trials, and post-marketing surveillance continues to capture such events. It is therefore important to consider the broader clinical picture when a patient taking gabapentin notices changes in their hair, rather than dismissing the concern outright or attributing it to the medication without further investigation.

What the Clinical Evidence Says About Gabapentin and Hair Loss

Peer-reviewed evidence directly linking gabapentin to hair loss is limited to sporadic case reports; no definitive causal link has been established in clinical trial data or current MHRA regulatory guidance.

Not sure if this is normal? Chat with one of our pharmacists →

Peer-reviewed literature specifically examining gabapentin as a direct cause of hair loss is limited. There are sporadic case reports and anecdotal accounts — including patient-reported experiences on pharmacovigilance databases such as the MHRA's Yellow Card scheme — that describe hair thinning or shedding in individuals taking gabapentin. However, these reports represent uncertain causality and cannot establish a definitive link on their own.

It is worth noting that gabapentin's structural analogue, pregabalin, has similarly sparse evidence linking it to alopecia. Some anticonvulsant medicines — most notably sodium valproate — are well-documented causes of hair loss, and this association may lead patients and clinicians to consider the possibility with other drugs in the broader anticonvulsant class. However, there is no officially established link between gabapentin and alopecia based on current MHRA regulatory guidance or robust clinical trial data, and alopecia is not recorded as a recognised adverse reaction in the UK SmPC for Neurontin.

The concept of telogen effluvium is relevant here. This is a form of diffuse hair shedding triggered by physiological stress, illness, nutritional deficiency, or medication changes. Any significant change in health status — including the underlying condition for which gabapentin is prescribed — could itself precipitate telogen effluvium, making it difficult to attribute hair loss solely to the drug. Clinicians are encouraged to consider the full timeline of hair loss onset relative to medication initiation, dose changes, and any concurrent health events.

Other Medications and Conditions That Can Cause Hair Loss

Sodium valproate, anticoagulants, beta-blockers, and thyroid dysfunction are among the most well-established causes of hair loss and should be excluded before attributing alopecia to gabapentin.

Before attributing hair loss to gabapentin, it is essential to consider the wide range of other medicines and medical conditions that are well-established causes of alopecia. This is particularly important because many patients taking gabapentin are also prescribed multiple other medications.

Medicines commonly associated with hair loss include:

• Sodium valproate and other anticonvulsants (e.g., carbamazepine)

• Anticoagulants such as warfarin and heparin

• Beta-blockers (e.g., propranolol, atenolol)

• Antidepressants, including SSRIs and SNRIs

• Retinoids and high-dose vitamin A

• Chemotherapy agents

• Hormonal contraceptives in some individuals

Medical conditions that frequently cause hair loss include:

• Hypothyroidism or hyperthyroidism — thyroid dysfunction is a particularly common and treatable cause

• Iron deficiency anaemia

• Alopecia areata (an autoimmune condition)

• Polycystic ovary syndrome (PCOS)

• Lupus and other connective tissue disorders

• Nutritional deficiencies, including low ferritin

In line with NICE CKS guidance on the assessment of hair loss, a structured approach should include a thorough medication review and targeted blood tests. First-line investigations typically include thyroid function (TSH), full blood count (FBC), and serum ferritin. Further tests should be guided by clinical findings rather than ordered routinely. Dermatological referral should be considered where the cause remains unclear after initial assessment.

Urgent referral to a dermatologist is warranted if any of the following are present:

• Scarring or fibrosis of the scalp

• Scalp pain, inflammation, or pustules

• Rapidly progressive or extensive hair loss

• Patchy loss with features suggesting a primary scalp disorder

Identifying a treatable underlying cause is always preferable to assuming a medication is responsible without evidence.

When to Speak to Your GP or Pharmacist

Patients noticing hair loss whilst taking gabapentin should consult their GP or pharmacist promptly and must not stop gabapentin abruptly, as withdrawal requires gradual tapering over at least one week.

If you are taking gabapentin and have noticed increased hair shedding, thinning, or patchy hair loss, it is advisable to speak to your GP or pharmacist rather than stopping the medication abruptly. Gabapentin should never be discontinued suddenly. The UK SmPC advises that gabapentin should be withdrawn gradually over a minimum of one week, and longer if clinically indicated. Abrupt discontinuation can trigger withdrawal symptoms including anxiety, insomnia, nausea, and — in those with epilepsy — an increased risk of seizures. Any dose reduction must be carried out under medical supervision.

You should contact your GP promptly if:

• Hair loss is sudden, severe, or occurring in distinct patches

• You notice hair loss alongside other new symptoms such as fatigue, weight changes, or skin changes (which may suggest a thyroid or autoimmune condition)

• Hair loss is causing significant distress or affecting your quality of life

• You have recently started gabapentin or had a dose increase and noticed a temporal relationship with hair changes

Your pharmacist can review your medicines, advise on potential contributing factors, and liaise with your GP regarding appropriate investigations or referral. Eligible patients may also benefit from a New Medicine Service (NMS) consultation or, where available, a Structured Medication Review (SMR) with a clinical pharmacist. It is important to bring a full list of all your current medications — including supplements — to any consultation, as interactions and cumulative effects can sometimes be overlooked.

Managing Hair Loss While Taking Gabapentin

Management should be collaborative, potentially including dose review, switching to an alternative such as amitriptyline or duloxetine per NICE CG173, correcting confirmed nutritional deficiencies, or dermatology referral.

If investigations reveal no identifiable medical cause for hair loss and a temporal association with gabapentin remains a possibility, management should be approached collaboratively between the patient and their prescribing clinician. The decision to continue, reduce, or switch medication must always weigh the therapeutic benefit of gabapentin against the impact of the side effect on the patient's wellbeing.

In practice, the following steps may be considered:

• Review the dose: In some cases, a lower effective dose may reduce the likelihood of side effects whilst maintaining therapeutic benefit. Refer to the BNF and SmPC for dosing guidance.

• Consider an alternative: Depending on the indication, alternative medicines may be appropriate. For peripheral neuropathic pain, NICE CG173 recommends amitriptyline, duloxetine, gabapentin, or pregabalin as first-line options. Any switch should be managed with appropriate cross-tapering under medical supervision, in line with BNF guidance.

• Address confirmed nutritional deficiencies: If blood tests identify iron deficiency or other deficiencies, targeted correction supports healthy hair growth. Routine supplementation with biotin or zinc is not recommended in the absence of confirmed deficiency. Patients and clinicians should also be aware that high-dose biotin supplementation can interfere with certain immunoassay laboratory tests, as highlighted in MHRA Drug Safety Update guidance.

• Dermatology referral: For persistent or distressing hair loss, a referral to a dermatologist can provide specialist assessment, including trichoscopy or scalp biopsy if indicated.

From a practical self-care perspective, patients are advised to use gentle shampoos, avoid excessive heat styling, and manage stress where possible, as psychological stress can itself perpetuate telogen effluvium. Emotional support and reassurance are also important, as hair loss — even when temporary — can significantly affect self-esteem and mental health.

MHRA Reporting and Patient Safety Considerations

Suspected adverse drug reactions, including hair loss potentially linked to gabapentin, should be reported via the MHRA Yellow Card scheme even when causality is uncertain, to support post-marketing safety surveillance.

The MHRA's Yellow Card scheme is the UK's pharmacovigilance system, enabling patients, carers, and healthcare professionals to report suspected adverse drug reactions (ADRs). If you or a patient believe that gabapentin may be contributing to hair loss, submitting a Yellow Card report is encouraged — even when the link is uncertain. These reports play a vital role in identifying rare or previously unrecognised side effects and contribute to ongoing post-marketing safety surveillance.

Yellow Card reports can be submitted online at yellowcard.mhra.gov.uk, via the Yellow Card app, or through a healthcare professional. When reporting, it is helpful to include:

• The dose and duration of gabapentin use

• The timeline of hair loss onset relative to starting the medication

• Any other medicines being taken concurrently

• Relevant medical history and investigation results

It is worth noting that gabapentin is a Class C controlled drug, placed in Schedule 3 in the UK following reclassification in April 2019, due to concerns about misuse and dependence. This reclassification has no direct bearing on its association with hair loss, but it underscores the importance of regular medication reviews and open communication between patients and prescribers.

From a patient safety perspective, the key message is that unexplained hair loss should always be investigated rather than assumed to be a medication side effect. Prompt identification of a treatable cause — such as thyroid dysfunction or iron deficiency — can lead to effective treatment and full recovery of hair growth. Healthcare professionals are encouraged to take patient-reported concerns seriously and to document and report any suspected ADRs through the appropriate channels.

Frequently Asked Questions